Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Intra-Cellular Therapies patents

List of Intra-Cellular Therapies patents

List of Skycross patents

List of Indian Institute Of Technology, Bombay patents

List of Carl Zeiss SMT patents

List of companies in Blue 9 Capital's investment portfolio

List of companies in Vestigium's investment portfolio

Patents where

Current Assignee

Name

is

Intra-Cellular Therapies

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 12023331 Methods	Patent 12023331 was granted and assigned to Intra-Cellular Therapies on July, 2024 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	12023331	July 2, 2024
	‌ US Patent 11124514 Compositions and methods	Patent 11124514 was granted and assigned to Intra-Cellular Therapies on September, 2021 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	11124514	September 21, 2021
	‌ US Patent 11096944 Organic compounds	Patent 11096944 was granted and assigned to Intra-Cellular Therapies on August, 2021 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	11096944	August 24, 2021
	‌ US Patent 9469647 Salt crystals	Patent 9469647 was granted and assigned to Intra-Cellular Therapies on October, 2016 by the United States Patent and Trademark Office.		Intra-Cellular Therapies		United States Patent and Trademark Office	9469647	October 18, 2016
	‌ US Patent 8779139 Substituted 2,3,4,4A,5,9B-hexahydro-1H-pyrido[4,3-B]indole derivatives synthesis and uses thereof	Patent 8779139 was granted and assigned to Intra-Cellular Therapies on July, 2014 by the United States Patent and Trademark Office.		Intra-Cellular Therapies		United States Patent and Trademark Office	8779139	July 15, 2014
	‌ US Patent RE48825 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms	Patent RE48825 was granted and assigned to Intra-Cellular Therapies on November, 2021 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	RE48825	November 23, 2021
	‌ US Patent 11166956 Combinations of PDE1 inhibitors and NEP inhibitors	Patent 11166956 was granted and assigned to Intra-Cellular Therapies on November, 2021 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	11166956	November 9, 2021
	‌ US Patent 8470548 Diagnosis of depression	Patent 8470548 was granted and assigned to Intra-Cellular Therapies on June, 2013 by the United States Patent and Trademark Office.		Intra-Cellular Therapies		United States Patent and Trademark Office	8470548	June 25, 2013
	‌ US Patent 12090155 Methods	Patent 12090155 was granted and assigned to Intra-Cellular Therapies on September, 2024 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	12090155	September 17, 2024
	‌ US Patent 11980617 Methods of treating acute depression and/or acute anxiety	Patent 11980617 was granted and assigned to Intra-Cellular Therapies on May, 2024 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	11980617	May 14, 2024
	‌ US Patent 11957791 Methods	Patent 11957791 was granted and assigned to Intra-Cellular Therapies on April, 2024 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	11957791	April 16, 2024
	‌ US Patent 12128043 Pharmaceutical capsules comprising lumateperone mono-tosylate	Patent 12128043 was granted and assigned to Intra-Cellular Therapies on October, 2024 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	12128043	October 29, 2024
	‌ US Patent 11839614 Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A	Patent 11839614 was granted and assigned to Intra-Cellular Therapies on December, 2023 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	11839614	December 12, 2023
	‌ US Patent 11872223 Amorphous solid dispersions	Patent 11872223 was granted and assigned to Intra-Cellular Therapies on January, 2024 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	11872223	January 16, 2024
	‌ US Patent 11958852 Compounds and methods	Patent 11958852 was granted and assigned to Intra-Cellular Therapies on April, 2024 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	11958852	April 16, 2024
	‌ US Patent 12070459 Pharmaceutical capsule compositions comprising lumateperone mono-tosylate	Patent 12070459 was granted and assigned to Intra-Cellular Therapies on August, 2024 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	12070459	August 27, 2024
	‌ US Patent 12122792 Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders	Patent 12122792 was granted and assigned to Intra-Cellular Therapies on October, 2024 by the United States Patent and Trademark Office.	Intra-Cellular Therapies	Intra-Cellular Therapies		United States Patent and Trademark Office	12122792	October 22, 2024

18 results

0 selected

18 results

0 selected